BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN)

CUSIP: 09061G101

Q2 2023 13F Holders as of 30 Jun 2023

Holder snapshot 7 signals
Share change
-391,556
Put/Call ratio
90%
SEC-reported price per share
$86.68
Indexed holders
548
Value change
-$55,787,524
Number of buys
256
Open additional details 1 more signal available
Number of sells
249
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
193,733,090

Security key

09061G101

Report period

Q2 2023

Indexed institutions

548

Top holders

10

Ownership snapshot

Top reported holders of BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
PRIMECAP MANAGEMENT CO/CA/
Disclosed value leader
PRIMECAP MANAGEMENT CO/CA/
Comparable rows
0/15
Latest evidence
31 Mar 2023
13F Highest disclosed value: $1,773,991,036 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

PRIMECAP MANAGEMENT CO/CA/ has the largest disclosed position value at $1.77B.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens PRIMECAP MANAGEMENT CO/CA/'s linked filing trail.
Disclosed position value Top 5
PRIMECAP MANAGEMENT CO/CA/ $1.77B
VANGUARD GROUP INC $1.7B
BlackRock Finance, Inc. $1.42B
DODGE & COX $1.39B
Capital Research Global Investors $700.96M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
PRIMECAP MANAGEMENT CO/CA/
13F
Company
13F
—
denominator unverified
$1,773,991,036
18,243,429 shares
— 31 Mar 2023
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$1,704,932,840
17,533,246 shares
— 31 Mar 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$1,423,455,129
14,638,576 shares
— 31 Mar 2023
DODGE & COX
13F
Company
13F
—
denominator unverified
$1,393,382,396
14,329,313 shares
— 31 Mar 2023
Capital Research Global Investors
13F
Company
13F
—
denominator unverified
$700,959,243
7,208,959 shares
— 31 Mar 2023
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$589,888,762
6,066,318 shares
— 31 Mar 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
548
Shares
178,653,463
Indexed holders
548
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 indexed holders
544
Q2 2023 indexed holders
548
Indexed holder difference
4
Investor Q1 2023 Shares Q2 2023 Shares Share Diff Share Chg % Q1 2023 value Q2 2023 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .